Table 1.
Demographics and co-morbidities (N = 25)
| n (%) | ||
|---|---|---|
| Biologic | Omalizumab | 2 (8) |
| Mepolizumab | 7 (28) | |
| Benralizumab | 15 (60) | |
| Dupilumab | 1 (4) | |
| Gender and age | Male | 9 (36) |
| Age 18–34 | 1 | |
| 35–49 | 1 | |
| 50–64 | 3 | |
| 65–79 | 4 | |
| Female | 16 (64) | |
| Age 18–34 | 2 | |
| 35–49 | 3 | |
| 50–64 | 7 | |
| 65–79 | 4 | |
| Ethnicity | Caucasian | 24 (96) |
| Mixed race | 1 (4) | |
| Age at onset | Adult | 17 (68) |
| Child | 8 (32) | |
| Smoking | Never | 17 (68) |
| Ex | 8 (32) | |
| Current | 0 | |
| Nasal polyps | Present 7 (28) | |
| Absent 18 (72) | ||
| Mean (range) | ||
| Age | 56 (56–77) | |
| BMI (Kg/m2) | 29.6 (21–47) | |
| Maximum Eosinophils in 12 months preceding biologic | 0.78 (0.2–1.48) | |
| Months since initiation# | 22 (7–44) | |
#4 participants had previously been on at least one other biologic